Navigation Links
Irritable Bowel Syndrome Therapeutics Clinical Trials H1 2015 Review Report Available at RnRMarketResearch.com
Date:2/19/2015

Dallas, TX (PRWEB) February 19, 2015

The clinical trial report “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015? provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. Irritable bowel syndrome is a general disorder that affects the large intestine. Irritable Bowel Syndrome is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient’s quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Complete report details available @ http://www.rnrmarketresearch.com/irritable-bowel-syndrome-global-clinical-trials-review-h1-2015-market-report.html .

The symptoms of Irritable bowel syndrome may include abdominal pain, bloating, cramping, constipation, gas and diarrhea. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable bowel syndrome.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report also includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this clinical trials report include GlaxoSmithKline plc, Novartis AG, Actavis plc, Astellas Pharma Inc., Salix Pharmaceuticals Ltd., Ironwood Pharmaceuticals, Inc., AstraZeneca PLC, Ono Pharmaceutical Co., Ltd., Almirall, S.A., A. Menarini Industrie Farmaceutiche Riunite Srl. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=268944 . (This is a premium report priced at US$2500 for a single user License.)

This report also includes the clinical trial overview of top institutes and government that includes Mayo Clinic, University of North Carolina, University of Nottingham, Maastricht University Medical Center, Sahlgrenska University Hospital, Chinese University of Hong Kong, Cedars-Sinai Medical Center, Karolinska Institute, University of California, Los Angeles, Baylor College of Medicine.

“Latest Clinical Trials News on irritable bowel syndrome”: Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation; Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan; Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation; Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation; Oct 21, 2014: Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea; Oct 17, 2014: Salix Pharmaceuticals Outlines Data of Rifaximin Presents at American College of Gastroenterology 2014 Annual Scientific Meeting.

Explore more reports on Clinical Trial industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .

More reports on Clinical Trials:

Steatohepatitis Global Clinical Trials Review, H1, 2015
This report provides elemental information and data relating to the clinical trials on Steatohepatitis. Companies discussed in this steatohepatitis clinical trials report include Genextra S.p.a., Galmed International Ltd., Raptor Pharmaceuticals Corp., Immuron Limited, Genfit SA, Cempra, Inc., Phenex Pharmaceuticals AG, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd., Catalysis, S.L.

Clinical trial overview of top institutes or government includes The National Institute of Diabetes and Digestive and Kidney Diseases, Tehran University of Medical Sciences, University of California, San Diego, Hadassah Medical Organization, Yokohama City University, Institute of Liver and Biliary Sciences, National Nutrition and Food Technology Research Institute, University Health Network, U.S. Department of Veterans Affairs, University of Michigan. Complete report details @ http://www.rnrmarketresearch.com/steatohepatitis-global-clinical-trials-review-h1-2015-market-report.html .

Cholelithiasis Global Clinical Trials Review, H1, 2015
This report provides elemental information and data relating to the clinical trials on Cholelithiasis. Companies and Institutes discussed in this report includes USGI Medical, Inc., Catalysis, S.L., Alternova A/S, University of California, San Diego, Islamic Azad University of Tabriz, Mansoura University, G. Hatzikosta General Hospital, Massachusetts General Hospital, University of California, San Francisco, Universidad Juarez Durango, Hospital Son Llatzer, Kuopio University Hospital, University of Missouri. Complete report details @ http://www.rnrmarketresearch.com/cholelithiasis-global-clinical-trials-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Read the full story at http://www.prweb.com/releases/irritable-bowel-syndrome/clinical-trials-review-h1/prweb12528984.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Experts Issue Guidelines for Treating Irritable Bowel Syndrome
2. MedicationDiscountCard.com Now Helps Sufferers of Irritable Bowel Syndrome
3. Pain treatments less effective for those with irritable bowel
4. Existing medicines show promise for treating stomach and bowel cancer
5. Grape seed promise in fight against bowel cancer
6. Gut microbes spur development of bowel cancer
7. MicroRNA could be key target for bowel cancer treatment
8. Two genes linked to inflammatory bowel disease
9. Wound-healing role for microRNAs in colon offer new insight to inflammatory bowel diseases
10. Growing up on a livestock farm halves the risk of inflammatory bowel diseases
11. Bowel cancer breakthrough may benefit thousands of patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... ... Month and the focus is on prostate cancer. Second only to skin cancer, prostate ... common cause of cancer related death today; lung cancer remains in the number one spot. ... during his lifetime. Those at highest risk are men who have a family ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and antioxidants derived ... loss in these patients. , But how often do ophthalmologists and optometrists in Sweden ... at risk of or with early symptoms of AMD? A study published recently ...
(Date:6/23/2017)... ... ... Goodcents Deli Fresh Subs today announced the opening of a new restaurant ... Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by long-time ... in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such a ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology: